Pressurised metered dose inhaler technology will be used in respiratory devices to treat COPD
Bespak, part of Consort Medical, and AstraZeneca have signed a multi-year scale-up and commercial supply agreement for Bespak's proprietary pressurised metered dose inhaler (pMDI) valve and actuator technology.
These components will be assembled with AstraZeneca’s Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
AstraZeneca announced that its device was approved by the US Food and Drug Administration on 25 April 2016.
These products will be manufactured in Bespak’s existing King’s Lynn facility. Going forwards the project will be referred to as VAL100.
'We are delighted to have successfully concluded this agreement with AstraZeneca,' said Jon Glenn, Chief Executive Officer of Consort Medical. 'This further reinforces the ongoing strength of our respiratory device franchise in the pMDI segment.'